Treatment of staphylococcal toxic epidermal necrolysis.
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D003348:Cortisone / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004009:Dicloxacillin / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007902:Length of Stay; D008297:Male; D009254:Nafcillin / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D009254:Nafcillin; D004917:Erythromycin; D003907:Dexamethasone; D004009:Dicloxacillin; D003348:Cortisone; D011241:Prednisone; D006854:Hydrocortisone